Cameron Lawrence, the Principal Accounting Officer, Treasurer and Senior Director, Finance of OncoGenex Pharmaceuticals, Inc. (the "Company"), will leave the Company effective May 31, 2012. The determination date for Mr. Lawrence's departure was May 25, 2012.

In connection with Mr. Lawrence's departure, he will receive a payroll check consisting of (i) amounts earned prior to May 31, 2012, (ii) an amount for accrued but untaken vacation time and (iii) a lump-sum of CDN$30,098.59. He will also be entitled to continued coverage under all group medical, dental and insurance plans, excluding short and long term disability plans and pension plan, to which he was entitled prior to his departure until the earlier of August 9, 2012 or the date he becomes employed elsewhere and is provided comparable coverage.

Additionally, if Mr. Lawrence agrees to release all claims against OncoGenex Technologies Inc., the Company's wholly-owned subsidiary (the "Subsidiary"), the Company and the Company's and Subsidiary's affiliates, Mr. Lawrence will also receive, in addition to the benefits described above, (i) a lump-sum payment of CDN$88,394.23, (ii) continued coverage under all group medical, dental and insurance plans, excluding short and long term disability plans and pension plan, until the earlier of February 28, 2013 or the date he becomes employed elsewhere and is provided comparable coverage and (iii) an opportunity to immediately exercise any of his outstanding stock options that would have vested between May 31, 2012 and February 28, 2013.

On May 31, 2012, the Company appointed Michelle Burris as the Principal Accounting Officer and Treasurer of the Company. Ms. Burris will continue to serve as the Executive Vice President, Operations, Chief Financial Officer and Secretary of the Company, positions she has held since January 2011.

Additional information regarding Ms. Burris is set forth under the heading "Executive Compensation" in the Company's definitive proxy statement on Schedule 14A filed on April 26, 2012, and is incorporated by reference herein.

On May 31, 2012, the Company held its 2012 Annual Meeting at which the Company's stockholders (i) elected the six nominees identified in the table below to the Board of Directors of the Company to serve until the Company's 2013 Annual Meeting of Stockholders or until successors are duly elected and qualified and
(ii) ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending December 31, 2012. Set forth below are the final voting tallies for the Company's 2012 Annual Meeting:

    Proposal: Election of Directors       For         Withheld       Broker Non-Vote
    Neil Clendeninn                     6,535,405        29,747             3,805,230
    Scott Cormack                       6,536,188        28,964             3,805,230
    Jack Goldstein                      6,535,885        29,267             3,805,230
    Martin Mattingly                    6,535,928        29,224             3,805,230
    Stewart Parker                      6,536,088        29,064             3,805,230
    David Smith                         6,535,658        29,494             3,805,230

Proposal: For Against Abstain Broker Non-Vote Ratification of Independent Auditor 10,263,349 86,965 20,068 0